Loomis, Sayles & Company
ROIV icon

Loomis, Sayles & Company’s Roivant Sciences ROIV Stock Holding History

Loomis, Sayles & Company’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,105,409
Closed -$23.7M – 756
2025
Q2 		$23.7M Sell
2,105,409
-352,443
-14% -$3.82M 0.03% 208
2025
Q1 		$24.8M Sell
2,457,852
-1,213,159
-33% -$13.1M 0.04% 208
2024
Q4 		$43.4M Sell
3,671,011
-241,194
-6% -$2.85M 0.05% 136
2024
Q3 		$45.1M Buy
3,912,205
+458,601
+13% +$5.22M 0.06% 143
2024
Q2 		$36.5M Buy
3,453,604
+260,262
+8% +$2.85M 0.05% 165
2024
Q1 		$33.7M Buy
3,193,342
+639,712
+25% +$6.9M 0.05% 181
2023
Q4 		$28.7M Buy
2,553,630
+568,695
+29% +$5.54M 0.04% 208
2023
Q3 		$23.2M Buy
1,984,935
+24,428
+1% +$276K 0.04% 227
2023
Q2 		$19.8M Buy
+1,960,507
New +$17.5M 0.03% 252

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Loomis, Sayles & Company's ROIV Position: Q3 2025 in Review

Loomis, Sayles & Company sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 2,105,409 shares — an estimated $23.7M sold.

Loomis, Sayles & Company first reported a position in ROIV in Q2 2023 and held it in 9 quarters. The position peaked at $45.1M in Q3 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Loomis, Sayles & Company reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Loomis, Sayles & Company sold 2,105,409 Roivant Sciences shares in Q3 2025, an estimated $23.7M.
  • Loomis, Sayles & Company first reported a position in Roivant Sciences in Q2 2023 and held it in 9 quarters.
  • Loomis, Sayles & Company's Roivant Sciences position peaked at $45.1M in Q3 2024.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Loomis, Sayles & Company's 13F filing for Q3 2025, filed 13 Nov 2025.